Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
1.09 USD -2.68% Intraday chart for Lineage Cell Therapeutics, Inc. -4.39% -.--%
Apr. 29 Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors CI
Mar. 11 Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive
PU
Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY
PU
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
BU
Lineage Announces Changes to Board of Directors
BU
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors
CI
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
BU
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT
AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
BU
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting
CI
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III
PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M
PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann
PU
Lineage Cell Therapeutics : FORM S-3-Registration Statements
PU
Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year
PU
Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. News Lineage Cell Therapeutics, Inc.